Abstract: Journal Pre-proof Impact of Antibody Cocktail Therapy Combined with Casirivimab and Imdevimab on Clinical Outcome for Covid-19 patients in A Real-Life Setting: A Single Institute Analysis Yasutaka Kakinoki , Kazuki Yamada , Yoko Tanino , Keiko Suzuki , Takaya Ichikawa , Naoki Suzuki , Go Asari , Ai Nakamura , Shin Kukita , Akito Uehara , Seisuke Saito , Shohei Kuroda , Hidemitsu Sakagami , Yuuki Nagashima , Kae Takahashi , Satoshi Suzuki PII: DOI: Reference: S1201-9712(22)00076-5 https://doi.org/10.1016/j.ijid.2022.01.067 IJID 5989 To appear in: International Journal of Infectious Diseases Received date: Revised date: Accepted date: 10 December 2021 18 January 2022 30 January 2022 Please cite this article as: Yasutaka Kakinoki , Kazuki Yamada , Yoko Tanino , Keiko Suzuki , Takaya Ichikawa , Naoki Suzuki , Go Asari , Ai Nakamura , Shin Kukita , Akito Uehara , Seisuke Saito , Shohei Kuroda , Hidemitsu Sakagami , Yuuki Nagashima , Kae Takahashi , Satoshi Suzuki , Impact of Antibody Cocktail Therapy Combined with Casirivimab and Imdevimab on Clinical Outcome for Covid-19 patients in A Real-Life Setting: A Single Institute Analysis, International Journal of Infectious Diseases (2022), doi: https://doi.org/10.1016/j.ijid.2022.01.067 This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. © 2022 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/) Highlights for review  Covid-19 patients with high-risk factors in a real-life practice were analyzed.  The cocktail combined with casirivimab and imdevimab was given consecutively.  The efficacy was compared with those patients without the cocktail.  The cocktail significantly reduced 70% in need of additional medical intervention. Impact of Antibody Cocktail Therapy Combined with Casirivimab and Imdevimab on Clinical Outcome for Covid-19 patients in A Real-Life Setting: A Single Institute Analysis Yasutaka Kakinoki, MD, PhD1), Kazuki Yamada, MD 1), Yoko Tanino, MD 1), Keiko Suzuki, MD 1), Takaya Ichikawa, MD 1), Naoki Suzuki, MD 2), Go Asari, BA 2), Ai Nakamura, MD 1), Shin Kukita, MD 1), Akito Uehara, MD 1), Seisuke Saito, MD 1), Shohei Kuroda, MD 1), Hidemitsu Sakagami, MD 1), Yuuki Nagashima, MD 1), Kae Takahashi, MD 1), and Satoshi Suzuki, MD 1) 1) Division of Internal Medicine, Asahikawa City Hospital, Asahikawa, Japan 2) Asahikawa City Health Center, Asahikawa, Japan Corresponding author: Yasutaka Kakinoki, MD, PhD. Asahikawa City Hospital, 1-1-65, Kinseicho, Asahikawa, 070-8610, Japan e-mail: y_kakinoki@ach.hokkaido.jp Keywords: Covid-19; SARS-CoV-2; cocktail; ronapreve; REGEN-COV ABSTRACT Background. Recent data from clinical trials suggest that antibody cocktail therapy with casirivimab and imdevimab is linked to reduction of the risk of hospitalization or death among high-risk patients with..